Revenue growth remains stagnant while gross margins have compressed from a 20.9% peak in 2024Q1 to 15.4% in 2026Q1, reflecting persistent competitive and cost pressures.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 5.82B | 5.81B | 5.78B | 6.08B | 6.83B | 6.34B | 4.97B | 5.53B | 6.64B | 6.18B | 5.4B | 5.72B | 6.43B | 6.86B | 7.37B |
| Revenue Growth % | 0.07% | 0.45% | -4.87% | -11.02% | 7.66% | 27.69% | -10.08% | -16.75% | 7.36% | 14.5% | -5.54% | -11.12% | -6.23% | -6.87% | - |
| Cost of Goods Sold | 4.94B | 4.91B | 4.63B | 4.77B | 5.21B | 4.96B | 3.9B | 4.46B | 4.67B | 4.43B | 4.29B | 4.76B | 5.07B | 5.39B | 5.01B |
| COGS % of Revenue | - | 84.47% | 80.09% | 78.51% | 76.34% | 78.23% | 78.53% | 80.76% | 70.31% | 71.63% | 79.44% | 83.3% | 78.86% | 78.66% | 68.08% |
| Gross Profit | 878M | 902M | 1.15B | 1.31B | 1.62B | 1.38B | 1.07B | 1.06B | 1.97B | 1.75B | 1.11B | 955M | 1.36B | 1.46B | 2.35B |
| Gross Margin % | 15.08% | 15.53% | 19.91% | 21.49% | 23.66% | 21.77% | 21.47% | 19.24% | 29.69% | 28.37% | 20.56% | 16.7% | 21.14% | 21.34% | 31.92% |
| Gross Profit Growth % | - | -21.63% | -11.87% | -19.18% | 17.02% | 29.43% | 0.38% | -46.07% | 12.37% | 58.02% | 16.23% | -29.78% | -7.1% | -37.73% | - |
| Operating Expenses | 922M | 907M | 708M | 1.43B | 830M | 707M | 619M | 616M | 739M | 682M | 1.01B | 729M | 828M | 932M | 892M |
| OpEx % of Revenue | - | 15.62% | 12.24% | 23.51% | 12.15% | 11.14% | 12.46% | 11.15% | 11.13% | 11.03% | 18.78% | 12.75% | 12.87% | 13.59% | 12.11% |
| Selling, General & Admin | 823M | 799M | 585M | 1.29B | 710M | 592M | 0 | 0 | 657M | 602M | 934M | 632M | 685M | 768M | 747M |
| SG&A % of Revenue | - | 13.76% | 10.12% | 21.22% | 10.39% | 9.33% | - | - | 9.9% | 9.74% | 17.3% | 11.05% | 10.65% | 11.2% | 10.14% |
| Research & Development | 107M | 108M | 109M | 108M | 118M | 107M | 93M | 80M | 82M | 80M | 80M | 97M | 143M | 164M | 145M |
| R&D % of Revenue | - | 1.86% | 1.89% | 1.78% | 1.73% | 1.69% | 1.87% | 1.45% | 1.24% | 1.29% | 1.48% | 1.7% | 2.22% | 2.39% | 1.97% |
| Other Operating Expenses | 1000K | 0 | 14M | 31M | 2M | 8M | 526M | 536M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -44M | -5M | 443M | -123M | 786M | 674M | 448M | 447M | 1.23B | 1.07B | 96M | 226M | 532M | 532M | 1.46B |
| Operating Margin % | -0.76% | -0.09% | 7.66% | -2.02% | 11.51% | 10.62% | 9.02% | 8.09% | 18.56% | 17.34% | 1.78% | 3.95% | 8.27% | 7.76% | 19.81% |
| Operating Income Growth % | - | -101.13% | 460.16% | -115.65% | 16.62% | 50.45% | 0.22% | -63.72% | 14.93% | 1016.67% | -57.52% | -57.52% | 0% | -63.54% | - |
| EBITDA | -132M | 335M | 744M | 184M | 1.08B | 991M | 768M | 715M | 1.52B | 1.34B | 380M | 493M | 789M | 793M | 1.73B |
| EBITDA Margin % | -2.27% | 5.77% | 12.87% | 3.03% | 15.77% | 15.62% | 15.46% | 12.94% | 22.84% | 21.75% | 7.04% | 8.62% | 12.27% | 11.56% | 23.42% |
| EBITDA Growth % | -118.26% | -54.97% | 304.35% | -82.92% | 8.68% | 29.04% | 7.41% | -52.84% | 12.71% | 253.95% | -22.92% | -37.52% | -0.5% | -54.03% | - |
| D&A (Non-Cash Add-back) | -88M | 340M | 301M | 307M | 291M | 317M | 320M | 268M | 284M | 273M | 284M | 267M | 257M | 261M | 266M |
| EBIT | 154M | -8M | 391M | -110M | 904M | 861M | 447M | 447M | 1.26B | 1.13B | 208M | 226M | 532M | 532M | 1.46B |
| Net Interest Income | -203M | -269M | -264M | -208M | -163M | -185M | -210M | -208M | -195M | -214M | -219M | -132M | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 134M | 269M | 264M | 208M | 163M | 185M | 210M | 208M | 195M | 215M | 219M | 132M | 0 | 0 | 0 |
| Other Income/Expense | -333M | -272M | -316M | -195M | -45M | 2M | -269M | -427M | -77M | -160M | -107M | -414M | 18M | 44M | 26M |
| Pretax Income | -377M | -277M | 127M | -318M | 741M | 676M | 179M | 20M | 1.16B | 912M | -11M | -188M | 550M | 576M | 1.49B |
| Pretax Margin % | -6.48% | -4.77% | 2.2% | -5.23% | 10.85% | 10.65% | 3.6% | 0.36% | 17.4% | 14.75% | -0.2% | -3.29% | 8.55% | 8.4% | 20.16% |
| Income Tax | 34M | 109M | 41M | -81M | 163M | 68M | -40M | 72M | 159M | 165M | -18M | -98M | 149M | 152M | 427M |
| Effective Tax Rate % | -9.02% | -39.35% | 32.28% | 25.47% | 22% | 10.06% | -22.35% | 360% | 13.77% | 18.09% | 163.64% | 52.13% | 27.09% | 26.39% | 28.75% |
| Net Income | -411M | -386M | 86M | -238M | 578M | 608M | 219M | -52M | 995M | 746M | 7M | -90M | 400M | 423M | 1.06B |
| Net Margin % | -7.06% | -6.65% | 1.49% | -3.92% | 8.46% | 9.58% | 4.41% | -0.94% | 14.99% | 12.07% | 0.13% | -1.57% | 6.22% | 6.17% | 14.35% |
| Net Income Growth % | -2057.14% | -548.84% | 136.13% | -141.18% | -4.93% | 177.63% | 521.15% | -105.23% | 33.38% | 10557.14% | 107.78% | -122.5% | -5.44% | -59.98% | - |
| Net Income (Continuing) | -411M | -386M | 86M | -237M | 578M | 608M | 219M | -52M | 996M | 747M | 7M | -90M | 401M | 424M | 1.06B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1M | 1M | 1M | 2M | 0 | 1M | 2M | 6M | 6M | 5M | 4M | 4M | 4M | 3M | 2M |
| EPS (Diluted) | -2.73 | -2.56 | 0.57 | -1.60 | 3.65 | 3.60 | 1.32 | -0.32 | 5.45 | 3.91 | 0.04 | -0.50 | 2.19 | 2.31 | 5.78 |
| EPS Growth % | -1395.86% | -549.12% | 135.63% | -143.84% | 1.39% | 172.73% | 512.5% | -105.87% | 39.39% | 9675% | 108% | -122.83% | -5.19% | -60.03% | - |
| EPS (Basic) | - | -2.57 | 0.58 | -1.60 | 3.72 | 3.69 | 1.33 | -0.32 | 5.62 | 4.04 | 0.04 | -0.50 | 2.21 | 2.33 | 5.83 |
| Diluted Shares Outstanding | 150.55M | 150.55M | 150.01M | 148.91M | 158.3M | 168.7M | 166.35M | 164.82M | 182.57M | 190.98M | 183.42M | 180.99M | 182.76M | 182.76M | 182.76M |
| Basic Shares Outstanding | 150.35M | 150.35M | 149.49M | 148.91M | 155.36M | 164.94M | 164.68M | 164.82M | 176.97M | 184.84M | 181.62M | 180M | 181.37M | 181.37M | 181.37M |
| Dividend Payout Ratio | - | - | 172.09% | - | 26.64% | 26.97% | 74.89% | - | 14.87% | 2.95% | 314.29% | - | - | - | - |
Legacy environmental liability exposure
According to the provided quarterly data, The Chemours Company has experienced largely stagnant top-line performance, with revenue growth fluctuating between -11.3% and 5.5% over the last ten quarters, reflecting the inherent volatility of the titanium dioxide market and broader industrial demand cycles.
The lack of consistent revenue expansion suggests that the company is struggling to offset cyclical downturns in its core Titanium Technologies segment with growth from its specialty fluorochemicals portfolio. Investors should monitor whether the current 1.0% revenue growth in 2026Q1 represents a stabilization point or merely a temporary reprieve from broader sector-wide demand contraction.
As reported in financial statements, gross margins have trended downward from a peak of 20.9% in 2024Q1 to 15.4% in 2026Q1, indicating that the company is facing significant challenges in maintaining pricing power against rising input costs and competitive pressures in the specialty chemicals space.
This margin erosion appears to be a structural concern rather than a transient issue, as the company struggles to pass through raw material inflation to its customers. The inability to sustain higher gross margins suggests that the competitive moat provided by its chloride-route manufacturing process may be insufficient to shield the firm from broader commodity price volatility.
Based on the company's reported figures, net income has been consistently impacted by significant volatility, including a sharp net loss of $381 million in 2025Q2, which highlights the distortive impact of legacy environmental litigation and restructuring costs on the firm's bottom-line performance.
The frequent divergence between operating income and net income suggests that headline EPS figures are unreliable indicators of core operational health. Analysts should exercise caution when evaluating these results, as the recurring nature of these non-operating charges may continue to mask the underlying cash-generative potential of the Opteon product line.
Data from recent income statements reveals erratic SG&A spending patterns, with periods of zero reported expense followed by spikes as high as $676 million in 2025Q4, suggesting that management is grappling with significant, unpredictable costs related to legal settlements and internal restructuring efforts.
The lack of consistent expense discipline in the SG&A line raises questions regarding the company's ability to manage its overhead effectively during periods of financial stress. This volatility warrants further investigation into whether these costs are truly non-recurring or if they represent a persistent burden that will continue to weigh on operating margins.
While the company maintains a specialized product portfolio, the persistent negative net margins and the potential for further litigation-related cash outflows, as suggested by the recent $676 million SG&A spike, present a significant risk to the company's long-term financial stability and capital allocation flexibility.
Short-sellers may focus on the company's inability to generate consistent positive net income, viewing the current financial profile as a sign of deeper, systemic issues related to legacy environmental liabilities. If the company cannot successfully transition its revenue mix toward higher-margin HFO products, the current cost structure may prove unsustainable in a high-interest-rate environment.
Quick answers to the most common questions about buying CC stock.
For fiscal year 2025, The Chemours Company (CC) reported total revenue of $5.81B. This represents a 21.1% decline compared to $7.37B in 2012.
The Chemours Company (CC) reported a net loss of $386.0M for the fiscal year ending 2025.
The Chemours Company (CC) reported an operating income of $-5.0M, resulting in an operating profit margin of -0.1%. This margin reflects the operational efficiency of the business before interest and taxes.
The Chemours Company (CC) generated $902.0M in gross profit for the year, representing a gross profit margin of 15.5%. This demonstrates the company's core pricing power and production efficiency.